Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B round brings $35mm to Atreca

Executive Summary

Atreca Inc. (cancer immunotherapies) raised $35mm through an oversubscribed Series B round. Wellington Management Co. and an undisclosed returning backer co-led the round and were joined by new investor Cormorant Asset Management and additional first-time and existing buyers. Funds will support development of Atreca's oncology candidates which were designed using the company's Immune Repertoire Capture technology.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Research, Analytical Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies